Gilead Sciences, INC Form 4 insider transactions
NASDAQ
Director Anthony Welters reports the acquisition of restricted stock units and stock options in Gilead Sciences, Inc.
NASDAQ
Director Harish Manwani reports acquisition of restricted stock units and stock options in Gilead Sciences, along with disposition of shares to cover tax obligations.
NASDAQ
Director Jeffrey Bluestone reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.
NASDAQ
Form 4: Gilead Sciences Director Sandra Horning Reports Stock Option and Restricted Stock Unit Grant
Director Sandra Horning reports the acquisition of stock options and restricted stock units in Gilead Sciences, Inc.
NASDAQ
Kelly A. Kramer, a director of Gilead Sciences, reported the acquisition of stock options and restricted stock units on May 8, 2024.
NASDAQ
EVP Deborah H. Telman of Gilead Sciences reports transactions involving common stock and restricted stock units.
NASDAQ
Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its holdings through the purchase of common stock and prefunded warrants.
NASDAQ
Gilead Sciences' Chief Medical Officer, Merdad Parsey, sold 2,000 shares of common stock on April 1, 2024, at a price of $72.96 per share, according to a Form 4 filing with the SEC.
NASDAQ
Director Kevin E. Lofton reports an acquisition of phantom stock in Gilead Sciences, Inc. through dividend equivalent rights.
NASDAQ
EVP Deborah H. Telman reports acquisition and disposal of Gilead Sciences stock and derivative securities.
NASDAQ
Form 4: Gilead Sciences SVP, Controllership, Sandra Patterson, Reports Changes in Beneficial Ownership
Sandra Patterson, SVP, Controllership at Gilead Sciences, reports transactions involving common stock and restricted stock units.
NASDAQ
Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Reports Changes in Beneficial Ownership
Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports transactions involving common stock and restricted stock units, including acquisitions, disposals, and vesting.
NASDAQ
Gilead Sciences CEO Daniel O'Day reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, in a recent SEC filing.
NASDAQ
Chief Commercial Officer Johanna Mercier reported transactions involving Gilead Sciences common stock and restricted stock units, including acquisitions and disposals related to vesting.
NASDAQ
Andrew Dickinson, CFO of Gilead Sciences, reports transactions involving common stock and restricted stock units, including acquisitions, disposals, and vesting.
NASDAQ
Chief Medical Officer of Gilead Sciences, Merdad Parsey, reports the sale of company stock under a pre-arranged trading plan.